Clinical trials: Prostate Disease
Prostate Cancer
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
The purpose of this trial is to compare the severity of ISRs (Injection Site Reactions) following degarelix subcutaneous (s.c.) administrations with two different injection techniques and intramuscular (i.m.) administration in…
- Trial name
- NCT02526784
- Testing
- degarelix
- Where
- 3 sites in Finland, France and 1 more
- Volunteers
- 120 people
- Sponsor
- Ferring Pharmaceuticals
Male Erectile Disorder, Prostate Cancer
Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery
The purpose of this study is to determine which technique in using a vacuum erection device (VED) is best. Erectile dysfunction (ED) after robotic prostate cancer surgery is a concern for both the surgeon and the patient.
- Conditions
- Male Erectile Disorder, Prostate Cancer, Sexual Dysfunction
- Trial name
- NCT01660152
- Testing
- Sexual Health Inventory for Men (SHIM) questionnaire administration, management of therapy complications, Daily vacuum therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer
Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in Men
Men with early prostate cancer face a number of options which lie at the extremes of care. On one hand, active surveillance involves monitoring the disease and on the other, immediate treatment involves surgery or radiotherapy.
- Trial name
- MAGNABLATE I (NCT02033447)
- Testing
- Magnetic Nanoparticle Injection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College London Hospitals
Prostate Cancer
Seoul National University Prospectively Enrolled Registry for Prostate Cancer With Active Surveillance
In this study, the investigators aim to establish the prostate cancer active surveillance prospective cohort in our institution, and finally investigate the 5 year rates of reclassification during active surveillance as the…
- Trial name
- SUPER-PC-AS (NCT02971085)
- Testing
- Active surveillance
- Where
- South Korea
- Volunteers
- 410 people
- Sponsor
- Seoul National University Hospital
Metastatic Cancer, Prostate Cancer
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084825
- Testing
- Docetaxel, Imatinib mesylate
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Diagnostic Imaging
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-7548 in patients with cancer.
- Trial name
- NCT01205321
- Testing
- Bombesin (68Ga) labeled (BAY86-7548)
- Where
- 3 sites in Finland, Germany and 1 more
- Volunteers
- 19 people
- Sponsor
- Lantheus Biosciences Ltd.
Prostate Cancer, Prostate
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
This expanded access protocol provides eligible participants with investigational 68Ga-PSMA-11 PET imaging to detect and localize prostate cancer for initial and subsequent treatment strategy.
- Conditions
- Prostate Cancer, Prostate, Prostate Adenocarcinoma
- Trial name
- NCT04377152
- Testing
- 68Gallium-PSMA-11, Positron Emission Tomography (PET)
- Where
- United States
- Sponsor
- University of California, San Francisco
Prostate Cancer
Robot-Assisted MRI-Guided Prostate Biopsy
Prostate biopsies are commonly performed freehanded under transrectal ultrasound guidance (TRUS). Due to the manual approach and the limitations of the ultrasound imager, the procedure has high false-negative rates.
- Trial name
- NCT02080052
- Testing
- Robot-assisted prostate biopsy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Adenocarcinoma
A Long Term Safety Study With Atrasentan
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
- Trial name
- NCT00127478
- Testing
- Atrasentan
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- Abbott
Prostate Cancer
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients…
- Trial name
- NCT03290508
- Testing
- Prolaris Testing
- Where
- 34 sites in United States
- Volunteers
- 524 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Prostate Cancer
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
This trial is an open-label, multi-centre, single arm extension for the 000006 trial in Chinese patients with prostate cancer. Eligible patients will receive monthly (28-day intervals) maintenance doses of 80 mg (20 mg/mL)…
- Trial name
- PandaExtension (NCT02015871)
- Testing
- Degarelix
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer, Prostate Cancer (Diagnosis)
Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise
Patients diagnosed with prostate cancer and receiving hormone therapy in conjunction with radiotherapy are likely to suffer from adverse effects caused by ADT treatment either short term or long term.
- Trial name
- ADHERE (NCT07243834)
- Testing
- Participation in a digital exercise intervention with virtual supervised group exercise sessions
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
PSA TOOL for Prostate Cancer Screening Discussions
The study team created a tool to help identify patients who may benefit from shared decision making in the primary care setting. This tool is a guide to aid in decision making for prostate cancer screening.
- Trial name
- NCT03135444
- Testing
- PSA TOOL, Revised PSA TOOL, Informal Interview
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Radiation-induced Diarrhoea in Prostate and Rectal Cancer
Radiation-induced Diarrhoea During Curative EBRT of Prostate and Rectal Cancer
Approx. 80% of patients with prostate and rectal cancer who receive radiation therapy (RT) experience acute radiation-induced diarrhea (RID).
- Trial name
- PRECANU (NCT05684432)
- Testing
- No intervention
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Aalborg University Hospital
Breast Cancer, Colorectal Cancer
SU006668 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs such as SU006668 may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU006668 in treating patients who have advanced solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer
- Trial name
- NCT00024063
- Testing
- orantinib
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Adjuvant Hypofractionated Radiotherapy for Prostate Cancer
Hypofractionated radiation therapy is a new type of radiotherapy which has been shown to play a larger role in the treatment of prostate cancer.
- Trial name
- NCT06335693
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Changhai Hospital
Prostate Cancer, Castrate Resistant Prostate Cancer
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
The purpose of this study is to access the safety of combining sodium selenite with abiraterone and to see what doses of sodium selenite can be safely combined with abiraterone in treating castration resistant prostate cancer.
- Trial name
- NCT04296578
- Testing
- Abiraterone Acetate, Sodium Selenite, Prednisone
- Sponsor
- Stanford University
Prostate, Prostate Cancer
Focal Therapy in Localized Prostate Cancer: a Prospective Registry
The principal aim of the registry is to collect data on focal therapy (FT) for the treatment of intermediate-risk prostate cancer across Europe.
- Trial name
- JR (NCT06772116)
- Testing
- Focal Therapy
- Volunteers
- 1,000 people
- Sponsor
- Institut Mutualiste Montsouris
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
The purpose of this study is to assess the efficacy and safety of opevesostat in the treatment of Japanese men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Next Generation Hormonal Agent…
- Trial name
- NCT06104449
- Testing
- Opevesostat, Dexamethasone, Fludrocortisone acetate
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.